Q-omics provides the consensus-scored KAT7 profile across patient tissues and cancer cell-line models. KAT7 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KAT7 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, KAT7 protein abundance shows 31,832 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where KAT7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KAT7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KAT7 survival associations across molecular data types. KAT7 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KAT7 RNA expression–survival associations across cancer types. High KAT7 expression shows unfavorable associations in LIHC, ACC and OV, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KAT7 RNA expression.
This table summarizes KAT7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KAT7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KAT7 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, LUSC and BRCA. The LIHC box plot shows higher KAT7 RNA expression in tumor versus normal tissue (log2 FC = +1.019, t-test p < 0.001).
This table shows molecular features associated with KAT7 in patient tissues and cancer cell lines. In patient samples, KAT7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KAT7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
